VANCOUVER, British Columbia, April 20, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Human Genome Sciences (NASDAQ:HGSI), Gilead Sciences (NASDAQ:GILD), Bristol Myers Squibb (NYSE:BMY), CVR Energy (NYSE:CVI), UnitedHealth Group (NYSE:UNH), and US Airways Group (NYSE:LCC).
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
Human Genome Sciences (NASDAQ:HGSI): Human Genome Sciences (NASDAQ:HGSI) announced on Thursday that it received a buyout offer from GlaxoSmithKline plc for approximately US$2.6 billion. This was rejected by Human Genome Sciences as the company considered that the offer does not reflect the value inherent in HGSI. Abnormal trading volume of Human Genome Sciences was found on Thursday, reaching 126.51 million shares, 21.7 times heavier than usual day trading. The stock advanced US$7.00 per share (equivalent to 97.63%), where stock prices went up to US$14.17. Why? Are insiders starting to take huge profits by selling shares or exercising stock options? Academic studies have shown that insiders traditionally make higher investment returns than ordinary investors. Want to find out how they do it?
Read Full Report: http://www.insiderslab.com/PR3/042012A/HGSI/HumanGenomeSciences.pdf
Gilead Sciences, Inc. (NASDAQ:GILD): Gilead Sciences, Inc. (NASDAQ:GILD) will publish its financial results for first quarter 2012 on Thursday, April 26. By the end of Thursday's trading, Gilead Sciences, Inc. soared 12.10% higher, moving up US$5.64 to US$52.25 per share. There were 35.97 million stock shares traded, which was 5.6 times more than average volume. Insiderslab.com believes that it is a clever way to check if insiders like CEOs, CFOs, and Directors in GILD are starting to buy more company shares. See insider trade report for GILD here.
Read Full Report: http://www.insiderslab.com/PR3/042012A/GILD/GileadSciences.pdf
Bristol Myers Squibb Co. (NYSE:BMY): Insiderslab.com found Market Sale (Planned) made by company Non-Executive Chairman of the Board -- James M. Cornelius on April 18, at stock price US$33.48. Disclose date: April 18. Bristol Myers Squibb Co. (NYSE:BMY) is scheduled to release its financial results for first quarter 2012 on April 26, 2012. By market close, Bristol Myers Squibb shares closed higher by 1.07% to US$33.93 with more than 23.42 million shares traded, compared to its average volume of 9.88 million shares. Investors may want to find out how company insiders like Executive Officers and Directors are thinking about the future business prospects of the company. Check this insider trade report for BMY here.
Read Full Report: http://www.insiderslab.com/PR3/042012A/BMY/BristolMyersSquibb.pdf
Today Insiderslab.com also observed abnormal trade volume for the following companies; insiders may involve trading in these companies. It will take some time for insiders to report their trades. Read these reports and add these companies into your Insider Trade Radar.
CVR Energy, Inc. (NYSE:CVI):
Read Full Report: http://www.insiderslab.com/PR3/042012A/CVI/CVREnergy.pdf
UnitedHealth Group Inc. (NYSE:UNH):
Read Full Report: http://www.insiderslab.com/PR3/042012A/UNH/UnitedHealthGroup.pdf
US Airways Group, Inc. (NYSE:LCC):
Read Full Report: http://www.insiderslab.com/PR3/042012A/LCC/USAirwaysGroup.pdf
Insider Filing Source Reference: All observations, analysis and reports are based on public information released by the U.S. Securities and Exchange Commission.
Insiderslab.com covers insider trade data in major stock markets in the U.S., Hong Kong, Mainland China, and Singapore. Insiderslab.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.
Please visit insiderslab.com/disclaimers/disclaimers.php for details.
SOURCE Insiderslab.com; Insiders.hk